Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.

Go here to see the original:
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

Related Posts